Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis.
Early diagnosis along with new drugs targeted to cancer receptors and immunocheckpoints have improved breast cancer survival. However, full remission remains elusive for metastatic breast cancer due to dose-limiting toxicities of heavily used, highly potent drug combinations such as gemcitabine and...
Main Authors: | Qingxin Mu, Jesse Yu, James I Griffin, Yan Wu, Linxi Zhu, Lisa A McConnachie, Rodney J Y Ho |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0228557 |
Similar Items
-
ICAM-1 Targeted Drug Combination Nanoparticles Enhanced Gemcitabine-Paclitaxel Exposure and Breast Cancer Suppression in Mouse Models
by: Linxi Zhu, et al.
Published: (2021-12-01) -
Design and Characterization of a Novel Venetoclax-Zanubrutinib Nano-Combination for Enhancing Leukemic Cell Uptake and Long-Acting Plasma Exposure
by: James Griffin, et al.
Published: (2023-03-01) -
What is unfair discrimination?
by: McConnachie, C
Published: (2012) -
What is unfair discrimination?
by: McConnachie, C
Published: (2014) -
Genetically modifying livestock for improved welfare: A path forward
by: Shriver, A, et al.
Published: (2018)